168 related articles for article (PubMed ID: 17276898)
1. Inhibition of infection caused by severe acute respiratory syndrome-associated coronavirus by equine neutralizing antibody in aged mice.
Zhou L; Ni B; Luo D; Zhao G; Jia Z; Zhang L; Lin Z; Wang L; Zhang S; Xing L; Li J; Liang Y; Shi X; Zhao T; Zhou L; Wu Y; Wang X
Int Immunopharmacol; 2007 Mar; 7(3):392-400. PubMed ID: 17276898
[TBL] [Abstract][Full Text] [Related]
2. Protection of mammalian cells from severe acute respiratory syndrome coronavirus infection by equine neutralizing antibody.
Wang X; Ni B; Du X; Zhao G; Gao W; Shi X; Zhang S; Zhang L; Wang D; Luo D; Xing L; Jiang H; Li W; Jiang M; Mao L; He Y; Xiao Y; Wu Y
Antivir Ther; 2005; 10(5):681-90. PubMed ID: 16152762
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the safety, immunogenicity and pharmacokinetics of equine anti-SARS-CoV F(ab')(2) in macaque.
Xu Y; Jia Z; Zhou L; Wang L; Li J; Liang Y; Zhao T; Ni B; Wu Y
Int Immunopharmacol; 2007 Dec; 7(13):1834-40. PubMed ID: 17996696
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of severe acute respiratory syndrome-associated coronavirus infection by equine neutralizing antibody in golden Syrian hamsters.
Zhao G; Ni B; Jiang H; Luo D; Pacal M; Zhou L; Zhang L; Xing L; Zhang L; Jia Z; Lin Z; Wang L; Li J; Liang Y; Shi X; Zhao T; Zhou L; Wu Y; Wang X
Viral Immunol; 2007; 20(1):197-205. PubMed ID: 17425434
[TBL] [Abstract][Full Text] [Related]
5. Protection from infection with severe acute respiratory syndrome coronavirus in a Chinese hamster model by equine neutralizing F(ab')2.
Luo D; Ni B; Zhao G; Jia Z; Zhou L; Pacal M; Zhang L; Zhang S; Xing L; Lin Z; Wang L; Li J; Liang Y; Shi X; Zhao T; Zou L; Wu Y; Wang X
Viral Immunol; 2007 Sep; 20(3):495-502. PubMed ID: 17931120
[TBL] [Abstract][Full Text] [Related]
6. Preparation and development of equine hyperimmune globulin F(ab')2 against severe acute respiratory syndrome coronavirus.
Lu JH; Guo ZM; Han WY; Wang GL; Zhang DM; Wang YF; Sun SY; Yang QH; Zheng HY; Wong BL; Zhong NS
Acta Pharmacol Sin; 2005 Dec; 26(12):1479-84. PubMed ID: 16297347
[TBL] [Abstract][Full Text] [Related]
7. Utility of the aged BALB/c mouse model to demonstrate prevention and control strategies for severe acute respiratory syndrome coronavirus (SARS-CoV).
Vogel LN; Roberts A; Paddock CD; Genrich GL; Lamirande EW; Kapadia SU; Rose JK; Zaki SR; Subbarao K
Vaccine; 2007 Mar; 25(12):2173-9. PubMed ID: 17227689
[TBL] [Abstract][Full Text] [Related]
8. Comparative evaluation of two severe acute respiratory syndrome (SARS) vaccine candidates in mice challenged with SARS coronavirus.
See RH; Zakhartchouk AN; Petric M; Lawrence DJ; Mok CPY; Hogan RJ; Rowe T; Zitzow LA; Karunakaran KP; Hitt MM; Graham FL; Prevec L; Mahony JB; Sharon C; Auperin TC; Rini JM; Tingle AJ; Scheifele DW; Skowronski DM; Patrick DM; Voss TG; Babiuk LA; Gauldie J; Roper RL; Brunham RC; Finlay BB
J Gen Virol; 2006 Mar; 87(Pt 3):641-650. PubMed ID: 16476986
[TBL] [Abstract][Full Text] [Related]
9. Development and characterization of a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody that provides effective immunoprophylaxis in mice.
Greenough TC; Babcock GJ; Roberts A; Hernandez HJ; Thomas WD; Coccia JA; Graziano RF; Srinivasan M; Lowy I; Finberg RW; Subbarao K; Vogel L; Somasundaran M; Luzuriaga K; Sullivan JL; Ambrosino DM
J Infect Dis; 2005 Feb; 191(4):507-14. PubMed ID: 15655773
[TBL] [Abstract][Full Text] [Related]
10. Neutralizing antibody against severe acute respiratory syndrome (SARS)-coronavirus spike is highly effective for the protection of mice in the murine SARS model.
Ishii K; Hasegawa H; Nagata N; Ami Y; Fukushi S; Taguchi F; Tsunetsugu-Yokota Y
Microbiol Immunol; 2009 Feb; 53(2):75-82. PubMed ID: 19291090
[TBL] [Abstract][Full Text] [Related]
11. Structural basis for potent cross-neutralizing human monoclonal antibody protection against lethal human and zoonotic severe acute respiratory syndrome coronavirus challenge.
Rockx B; Corti D; Donaldson E; Sheahan T; Stadler K; Lanzavecchia A; Baric R
J Virol; 2008 Apr; 82(7):3220-35. PubMed ID: 18199635
[TBL] [Abstract][Full Text] [Related]
12. Complete protection against severe acute respiratory syndrome coronavirus-mediated lethal respiratory disease in aged mice by immunization with a mouse-adapted virus lacking E protein.
Fett C; DeDiego ML; Regla-Nava JA; Enjuanes L; Perlman S
J Virol; 2013 Jun; 87(12):6551-9. PubMed ID: 23576515
[TBL] [Abstract][Full Text] [Related]
13. Prior immunization with severe acute respiratory syndrome (SARS)-associated coronavirus (SARS-CoV) nucleocapsid protein causes severe pneumonia in mice infected with SARS-CoV.
Yasui F; Kai C; Kitabatake M; Inoue S; Yoneda M; Yokochi S; Kase R; Sekiguchi S; Morita K; Hishima T; Suzuki H; Karamatsu K; Yasutomi Y; Shida H; Kidokoro M; Mizuno K; Matsushima K; Kohara M
J Immunol; 2008 Nov; 181(9):6337-48. PubMed ID: 18941225
[TBL] [Abstract][Full Text] [Related]
14. Chimeric severe acute respiratory syndrome coronavirus (SARS-CoV) S glycoprotein and influenza matrix 1 efficiently form virus-like particles (VLPs) that protect mice against challenge with SARS-CoV.
Liu YV; Massare MJ; Barnard DL; Kort T; Nathan M; Wang L; Smith G
Vaccine; 2011 Sep; 29(38):6606-13. PubMed ID: 21762752
[TBL] [Abstract][Full Text] [Related]
15. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody.
Pinto D; Park YJ; Beltramello M; Walls AC; Tortorici MA; Bianchi S; Jaconi S; Culap K; Zatta F; De Marco A; Peter A; Guarino B; Spreafico R; Cameroni E; Case JB; Chen RE; Havenar-Daughton C; Snell G; Telenti A; Virgin HW; Lanzavecchia A; Diamond MS; Fink K; Veesler D; Corti D
Nature; 2020 Jul; 583(7815):290-295. PubMed ID: 32422645
[TBL] [Abstract][Full Text] [Related]
16. Virus-specific memory CD8 T cells provide substantial protection from lethal severe acute respiratory syndrome coronavirus infection.
Channappanavar R; Fett C; Zhao J; Meyerholz DK; Perlman S
J Virol; 2014 Oct; 88(19):11034-44. PubMed ID: 25056892
[TBL] [Abstract][Full Text] [Related]
17. Receptor-binding domain of SARS-CoV spike protein induces long-term protective immunity in an animal model.
Du L; Zhao G; He Y; Guo Y; Zheng BJ; Jiang S; Zhou Y
Vaccine; 2007 Apr; 25(15):2832-8. PubMed ID: 17092615
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of human monoclonal antibody 80R for immunoprophylaxis of severe acute respiratory syndrome by an animal study, epitope mapping, and analysis of spike variants.
Sui J; Li W; Roberts A; Matthews LJ; Murakami A; Vogel L; Wong SK; Subbarao K; Farzan M; Marasco WA
J Virol; 2005 May; 79(10):5900-6. PubMed ID: 15857975
[TBL] [Abstract][Full Text] [Related]
19. SARS coronavirus spike polypeptide DNA vaccine priming with recombinant spike polypeptide from Escherichia coli as booster induces high titer of neutralizing antibody against SARS coronavirus.
Woo PC; Lau SK; Tsoi HW; Chen ZW; Wong BH; Zhang L; Chan JK; Wong LP; He W; Ma C; Chan KH; Ho DD; Yuen KY
Vaccine; 2005 Oct; 23(42):4959-68. PubMed ID: 15993989
[TBL] [Abstract][Full Text] [Related]
20. Antibodies against trimeric S glycoprotein protect hamsters against SARS-CoV challenge despite their capacity to mediate FcgammaRII-dependent entry into B cells in vitro.
Kam YW; Kien F; Roberts A; Cheung YC; Lamirande EW; Vogel L; Chu SL; Tse J; Guarner J; Zaki SR; Subbarao K; Peiris M; Nal B; Altmeyer R
Vaccine; 2007 Jan; 25(4):729-40. PubMed ID: 17049691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
